Latest Health News

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

D3 Energy has reported encouraging progress in its South African helium and methane operations, highlighted by improved gas flow rates from the Nooitgedacht Major well and an upgraded US OTCQX listing to broaden investor reach.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Perpetual Limited’s second quarter FY26 update reveals a mixed performance with strong Corporate Trust growth balancing net outflows in Asset Management, while Wealth Management remains stable amid ongoing sale talks.

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.

Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.